

(Mobile book) State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 3.: Defining the Next Generation of Analytical and Biophysical Techniques. (ACS Symposium Series)

## State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 3.: Defining the Next Generation of Analytical and Biophysical Techniques. (ACS Symposium Series)

From American Chemical Society  
ebooks | Download PDF | \*ePub | DOC | audiobook



 Download

 Read Online

#528895 in Books 2016-06-24Original language:English 6.20 x 1.20 x 9.10l, .0 #File Name: 0841230315464 pages | File size: 73.Mb

**From American Chemical Society : State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 3.: Defining the Next Generation of Analytical and Biophysical Techniques. (ACS Symposium Series)** before purchasing it in order to gage whether or not it would be worth my time, and all praised State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 3.: Defining the Next Generation of Analytical and Biophysical Techniques. (ACS Symposium Series):

This volume describes novel and emerging analytical technologies for analysis of proteins with the emphasis on technologies aimed to address characterization "knowledge gaps" and/or improve our ability to measure specified attributes with improved selectivity, sensitivity, resolution, and throughput. Higher order structure of proteins is a recognized important attribute of mAbs, with potential implications on stability, safety, and biological function of these large molecules. This book, the last in a series of three volumes, touches on topics ranging from X-ray crystallography, NMR, hydrogen-deuterium exchange mass spectrometry, covalent labeling techniques, and ion mobility mass spectrometry.

**About the Author** Dr. John E. Schiel received his B.S. (2004) and Ph.D.(2009) in Chemistry from the University of Nebraska-Lincoln, and is currently a research chemist in the NIST Biomolecular Measurement Division. Dr. Darryl L. Davis holds a doctorate in Medicinal Chemistry from the Philadelphia College of Pharmacy and Science. Currently he leads an analytical group within the discovery organization at Janssen RD. Dr. Oleg V. Borisov earned a B.S. degree (with honors) in Chemistry at Moscow State University (1992), and received his Ph.D. in Chemistry from Wayne State University (1997), after which he completed his post-doctoral studies at Lawrence Berkeley National Laboratories (2000) and Pacific Northwest National Laboratories (2001). He is currently a Director at Novavax, Inc., developing methods and strategies for analysis and characterization of recombinant vaccines, based on nano- and virus-like particle technologies.